Claforan Side Effects
Generic Name: cefotaxime
Note: This page contains information about the side effects of cefotaxime. Some of the dosage forms included on this document may not apply to the brand name Claforan.
Not all side effects for Claforan may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to cefotaxime: injection powder for solution
In addition to its needed effects, some unwanted effects may be caused by cefotaxime (the active ingredient contained in Claforan). In the event that any of these side effects do occur, they may require medical attention.
If any of the following side effects occur while taking cefotaxime, check with your doctor or nurse immediately:Less common
- Abdominal or stomach cramps or tenderness
- black, tarry stools
- chest pain
- diarrhea, watery and severe, which may also be bloody
- difficulty with breathing
- difficulty with swallowing
- fast heartbeat
- increased thirst
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- nausea or vomiting
- noisy breathing
- painful or difficult urination
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- shortness of breath
- skin rash
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- swollen glands
- tightness in the chest
- unusual bleeding or bruising
- unusual tiredness or weakness
- unusual weight loss
- back, leg, or stomach pains
- bleeding gums
- blistering, peeling, or loosening of the skin
- blood in the urine or stools
- bloody or cloudy urine
- blurred vision
- cough or hoarseness
- cracks in the skin at the corners of the mouth
- dark urine
- fast, slow, or irregular heartbeat
- fever with or without chills
- general body swelling
- general feeling of tiredness or weakness
- greatly decreased frequency of urination or amount of urine
- itching of the vagina or genital area
- joint or muscle pain
- loss of appetite
- lower back or side pain
- mood or mental changes
- pain during sexual intercourse
- pale skin
- pinpoint red spots on the skin
- red skin lesions, often with a purple center
- red, irritated eyes
- soreness or redness around the fingernails and toenails
- stiff neck
- swelling of the feet or lower legs
- thick, white vaginal discharge with no odor or with a mild odor
- yellowing of the eyes or skin
- Clay-colored stools
- unpleasant breath odor
- vomiting of blood
Some of the side effects that can occur with cefotaxime may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Red streaks on the skin
- swelling, tenderness, or pain at the injection site
For Healthcare Professionals
Applies to cefotaxime: injectable powder for injection, intravenous solution
The majority of cefotaxime (the active ingredient contained in Claforan) adverse effects are mild and transient and rarely require discontinuation of the medication.
Gastrointestinal side effects have included colitis, nausea, vomiting, and diarrhea in 1.4% of patients. Clostridium difficile associated diarrhea has been reported with almost all antibiotics, including the cephalosporins.
Clostridium difficile should be suspected in any patient who develops persistent or severe diarrhea following cephalosporin therapy.
One small study indicates that elderly patients treated with cefotaxime may be more likely than younger patients to experience Clostridium difficile colitis.
Hypersensitivity reactions, such as rash and pruritus, are relatively uncommon, but may require discontinuation of the drug.
A 75-year-old female developed toxic epidermal necrolysis (TEN) over 40% of her body surface area after receiving cefotaxime (the active ingredient contained in Claforan) for 6 days. After cefotaxime discontinuation and some improvement, meropenem was started. The TEN immediately recurred and spread to previously unaffected areas of the skin, and the patient died. The authors recommend avoiding chemically similar drugs to the precipitating drug when treating patients with drug-induced TEN.
A case of occupational contact dermatitis due to cephalosporin allergy has been reported in a nurse who prepared cephalosporin solutions for administration to patients. The dermatitis resolved after the nurse stopped preparing the solutions.
Hypersensitivity side effects have included rash, pruritus, fever, eosinophilia, urticaria, and anaphylaxis (e.g., angioedema, bronchospasm, malaise possibly culminating in shock) in 2.4% of patients. Allergic cross-reactivity with penicillin and carbapenems may occur. Cases of Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis have been reported. Allergic reactions have been reported with cephalosporins as a class.
Other side effects have included overgrowth of nonsusceptible organisms and have resulted in superinfection. False-positive test for urinary glucose have been reported with cephalosporins as a class.
Local side effects have included injection site inflammation and phlebitis with intravenous administration and pain, induration, and tenderness following intramuscular injection in 4.3% of patients.
Nervous system side effects have included headache and encephalopathy (e.g., impairment of consciousness, abnormal movements, and convulsions) in less than 1% of patients. Some cephalosporins have been associated with seizures, particularly in renally impaired patients when the dosage was not reduced.
Administration of high doses of beta-lactams, including cefotaxime, particularly in patients with renal insufficiency may result in encephalopathy.
In one case, a 68-year-old man with moderate renal insufficiency underwent surgery for repair of an abdominal aortic aneurysm. He developed renal failure requiring hemodialysis. Cefotaxime was administered for an abdominal abscess. The patient developed encephalopathic symptoms. Cefotaxime was discontinued and hemodialysis was performed. The mental status of the patient improved. Cefotaxime was reinstituted. No further toxicity occurred.
Hepatic side effects have included transient elevations in SGOT, SGPT, serum lactate dehydrogenase, gamma glutamyltransferase, bilirubin, and serum alkaline phosphatase in less than 1% of patients. These laboratory abnormalities (which may be due to the infection) may rarely exceed twice the upper limit of the normal and elicit a pattern of liver injury, usually cholestatic and most often asymptomatic. Hepatitis, sometimes with jaundice, has been reported. Cephalosporins as a class have been associated with hepatic dysfunction including cholestasis.
Unlike other cephalosporins, severe alterations in coagulation parameters have not been reported in association with cefotaxime (the active ingredient contained in Claforan) therapy. The methylthiotetrazole moiety found on other cephalosporins may be responsible for the development of coagulation defects.
Hematologic side effects have included granulocytopenia, eosinophilia, transient leukopenia, neutropenia, thrombocytopenia, agranulocytosis, positive direct Coombs' tests, and hemolytic anemia in less than 1% of patients. Cephalosporins as a class have been associated with aplastic anemia, prolonged prothrombin time, and hemorrhage.
Renal side effects have included interstitial nephritis and transient increases in BUN and creatinine in less than 1% of patients. Reversible fever, azotemia, pyuria, and eosinophilia are the hallmarks of cephalosporin-induced interstitial nephritis. Cephalosporins as a class have been associated with renal dysfunction and toxic nephropathy.
Dermatologic side effects have included rash, urticaria, pruritus, and cases of erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and telangiectasia.
Cardiovascular side effects have included potentially life-threatening arrhythmias following rapid (less than 60 seconds) bolus administration through a central venous catheter (less than 1%).
Genitourinary side effects have included moniliasis and vaginitis.
More about Claforan (cefotaxime)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.